610
mAbexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Jun 12, 2020 (NCT04445038)
Timeline
Indications
Studied for
Mechanism of action
- Interleukin-5INHIBITOR
IL5 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06680947 | Phase 2 | Nov 30, 2024 | Jiao Tong University, Sunshine Lake Pharma Co., Ltd. |
| NCT06323213 | Phase 3 | Apr 30, 2024 | Jiao Tong University, Sunshine Lake Pharma Co., Ltd. |
| NCT05528679 | Phase 2 | Sep 30, 2022 | Jiao Tong University, Sunshine Lake Pharma Co., Ltd. |
| NCT05584306 | Phase 1 | Dec 6, 2021 | Jiao Tong University, Sunshine Lake Pharma Co., Ltd. |
| NCT04445038 | Phase 1 | Jun 12, 2020 | Jiao Tong University, Sunshine Lake Pharma Co., Ltd. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiao Tong University | Academic/Hospital | 5 | 0 | 3 | 2020 |
| Sunshine Lake Pharma Co., Ltd. | For profit | 5 | 5 | 3 | 2020 |
2 organizations
Page 1 / 1